Effects of dietary Fusarium mycotoxins on intestinal lymphocyte subset populations, cell proliferation and histological changes in avian lymphoid organs

2010 ◽  
Vol 48 (10) ◽  
pp. 3000-3007 ◽  
Author(s):  
C.K. Girish ◽  
T.K. Smith ◽  
H.J. Boermans ◽  
P. Anil Kumar ◽  
G.N. Girgis
Development ◽  
1966 ◽  
Vol 15 (1) ◽  
pp. 67-76
Author(s):  
Allan L. Allenspach

In an earlier publication (Allenspach & Hamilton, 1962) an account was given of chick esophageal development and histogenesis up to 10 days of incubation. The esophagus becomes completely occluded at 5 days (stage 26, Hamburger & Hamilton, 1951) and reopens rapidly at 7½–8 days (stages 33–34). Detailed observations were made of the histological changes in the organs as correlated with the localization of ribonucleic acid and alkaline phosphatase. The occlusion of the developing esophagus was apparently due to collapse and adhesion of roof and floor epithelia to form a solid epithelial bar and not to cell proliferation, as stated in Lillie's Development of the Chick (Hamilton, 1952, pp. 384–5). This process was the object of further investigation in which the role of proliferation in occlusion was determined by the use of colchicine. Results indicated that cell proliferation is not involved in the closing process (Allenspach, 1964).


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5287-5287
Author(s):  
Emilio Cosimo ◽  
Anuradha Tarafdar ◽  
Ailsa Holroyd ◽  
Karen Dunn ◽  
Mark Catherwood ◽  
...  

Abstract Chronic lymphocytic leukaemia (CLL), often diagnosed in the elderly, is incurable with current therapeutic regimes. Recent studies demonstrate that the microenvironment within CLL patient lymphoid organs protects leukaemic cells from chemotherapy induced apoptosis. This highlights the need for novel therapies that can overcome such cytoprotective signals. Serine/threonine protein kinase mammalian target for rapamycin (mTOR) is a key regulator of cell survival and proliferation and is commonly deregulated in cancer. mTOR is active in two complexes mTORC1 and mTORC2. We demonstrate that mTORC1 and mTORC2 substrates, including S6 (pS6S235/236) and Akt (pAktS473) respectively, are active although differentially regulated, in CLL cells from distinct prognostic subsets ex vivo, which suggests that mTOR may represent a valid therapeutic target for CLL. Initial studies with everolimus, an analogue of rapamycin, showed only limited antitumor activity in recurrent/refractory CLL patients, possibly because mTORC1 inhibition releases the "brake" that normally active mTORC1 has on mTORC2, thus enabling mTORC2 mediated signalling. To test the impact of inhibiting both mTORC1 and mTORC2 on cell proliferation and survival, we treated primary CLL cells and an aggressive CLL mouse model with the novel ATP-competitive mTOR inhibitor AZD8055 in vitro and in vivo. CLL proliferation and mTORC1/2 activity were significantly reduced upon addition of AZD8055 to NTL-CD154/IL4 co-cultures, which mimic pro-proliferative conditions present in the microenvironment of lymphoid organs. However, in the same conditions use of AZD8055 did not induce apoptosis at clinically-achievable drug concentrations (<150 nM), likely due to ineffective inhibition of Mcl-1 upregulation mediated by the NTL-CD154/IL4 co-cultures. In contrast, B cell receptor (BCR)-mediated survival was inhibited by AZD8055 treatment, inducing significant levels of apoptosis, concomitant with a decreased Mcl-1 expression. These findings suggest that the BCR and CD154/IL4 mediated pathways regulate Mcl-1 expression by distinct mechanisms. In vivo studies using the PKCa-KR-induced CLL mouse model revealed that AZD8055 treatment efficiently reduced tumour burden in the organs (spleen and bone marrow) and blood of mice with established CLL. This was reflected by in vitro studies showing that use of AZD8055 increased apoptosis and reduced proliferation in mouse CLL cells. Overall these data indicate that AZD8055 inhibits CLL proliferation, in vitro and in vivo, and disrupts BCR mediated survival, by downregulating Mcl-1 protein levels. Therefore dual mTOR inhibitors through reduction of tumour burden, show promise as a future therapy for CLL. Disclosures No relevant conflicts of interest to declare.


1979 ◽  
Vol 149 (2) ◽  
pp. 516-534 ◽  
Author(s):  
A N Theofilopoulos ◽  
R A Eisenberg ◽  
M Bourdon ◽  
J S Crowell ◽  
F J Dixon

The frequencies and absolute numbers of B and T cells in the lymphoid organs of five murine strains (NZB, (NZB X NZW)F1, BXSB, MRL/l, and MRL/n) with SLE-like syndromes were examined. We assessed the frequencies of cells bearing surface Ig, C3d and IgG Fc receptors, and theta-antigen. The sequential expression of Ig isotopes on developing B cells and the Ig isotypes expressed on adult B cells were ascertained. In addition, the Ly subsets and the expression of Ia antigens coded for by the I-J subregion of the mouse H-2 complex were examined. Compared to normal, older mice, New Zealand mice had low frequencies and absolute numbers of B cells, BXSB mice had a moderate B-cell proliferation, and MRL/l mice had normal absolute numbers of B cells but a reduced frequency concomitant with a massive T-cell proliferation. Old New Zealand mice and BXSB mice had reduced frequencies and absolute numbers of T cells compared to old controls. The developmental Ig-isotype diversity during the 1st wk of age was similar in normal mice and those with autoimmune manifestations. Mature B cells were present in lymphoid organs of New Zealand mice and BXSB mice as evidenced by the high frequency of C3d receptor-bearing cells and Ig-isotype expression (high ratio of IgM- to IgD-bearing cells) in adult spleen cells. Numbers of IgG Fc receptor-bearing cells were reduced in autoimmune mice with advanced age and disease. The proliferating T cells in MRL/l mice were found to be theta-antigen positive but Ly null. These theta+-, Ly null cells may have arisen from Ly123+ T cells. MRL/l and BXSB mice seemed normal in their content of T cells bearing Ia antigens coded for by the I-J subregion of H-2. Overall, mice with autoimmune manifestations appear to express perturbations in T and B cells with development of disease, and their patterns of change vary from one strain to another.


2017 ◽  
Vol 10 (1) ◽  
pp. 89-96 ◽  
Author(s):  
A.P.F.L. Bracarense ◽  
K.M. Basso ◽  
E.O. Da Silva ◽  
D. Payros ◽  
I.P. Oswald

Deoxynivalenol (DON) is one of the most prevalent type B trichothecenes present in food inducing adverse effects, including intestinal changes and immunosuppression. The aim of the present study was to investigate the effects of DON on rats exposed for 7, 14 and 28 days to mycotoxin-contaminated diets, using histological and immunohistochemical analyses on liver and lymphoid organs. Fifty rats received a control diet, or a diet contaminated with 1.75 mg/kg of DON for 30 days, or a diet contaminated with 11.4 mg/kg of DON for 7, 14 or 30 days. Ingestion of contaminated feed induced a significant increase in the lesional score in the liver, spleen, and lymph nodes. The main histological findings observed in the liver were cytoplasmic vacuolisation and hepatocelular megalocytosis. A significant increase in hepatocyte proliferation was observed in rats that received 1.75 mg/kg of DON. Lymphoid depletion was the main histological alteration observed in lymphoid organs, resulting in a significant increase in the lesional score in all groups that received the contaminated diets. The histological changes and lymphocyte apoptosis were more severe in lymph nodes of rats fed 11.4 mg/kg of DON during 30 days. The results of the morphological and immunohistochemical analyses suggest that the ingestion of DON can induce functional hepatic impairment and immunosuppression in a dose- and time-dependent manner.


1984 ◽  
Vol 74 (2) ◽  
pp. 172-177 ◽  
Author(s):  
Alain Pompidou ◽  
Micheline Renoux ◽  
Jean-Maurice Guillaumin ◽  
Bertrand Macé ◽  
Paule Michel ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Tao Yuan ◽  
Ni Yang ◽  
Wei Bi ◽  
Jinwen Zhang ◽  
Xueyan Li ◽  
...  

Background. Though widely known as a potent antithrombin agent with protective effects on the kidney and other remote organs, it is currently ambiguous when it comes to sulodexide’s function on ischemia-reperfusion (I/R) injury. With this research, we pursued to further explore how sulodexide exerts its influence on limb I/R injury, in which deleterious effects on the kidney were what we primarily focused on. Methods. We randomized twenty-four C57BL/6 male rats into three groups, namely, sham operation group (control group), I/R group, and sulodexide pretreatment group. Hematoxylin and eosin staining was applied for discovery of renal histological changes. Serum creatinine (Cr) and serum urea nitrogen (BUN) were measured. Apoptotic parameters were detected by the TdT-mediated dUTP Nick-End Labeling method. To what extent and levels that antiapoptotic and proapoptotic proteins were expressed could be sensitively revealed by immunohistochemistry assay. Lipid peroxidation product propylene glycol and inflammatory factors were examined by enzyme-linked immunosorbent assay. Additionally, an extracorporeal hypoxia-reoxygenation (H/R) model of human renal proximal tubule epithelial HK2 cells was established. Our targets lay in cell proliferation and apoptosis, and we used western blotting to reflect apoptosis-related gene expression. Results. The levels of serum BUN, Cr, and inflammatory factors in sulodexide-intervened rats manifested significant reduction when compared with the I/R group. Also, sulodexide could protect the kidney from histological changes and could effectively inhibit intraparenchymal apoptosis. Furthermore, adding 2 μl/mL or 5 μl/mL of sulodexide to H/R model cells in vitro gave rise to significant restoration of the degenerative proliferation capacity of the HK2 cells following H/R injury and late cellular apoptosis experienced dramatic reduction versus the H/R group. When treated with 5 μl/mL of sulodexide at a dose of 10 mg/kg, the levels of the antiapoptotic proteins were increased, while the proapoptotic proteins showed opposite trends. Notable escalation on antiapoptotic protein expression level, in contrast with the opposite trends exhibited in proapoptotic proteins, was observed with 5 μl/mL sulodexide pretreatment with the dosage being 10 mg/kg. Conclusion. Sulodexide can protect against kidney damage caused by I/R injury of the lower limbs by enhancing cell proliferation, inhibiting apoptosis, reducing inflammatory reactions, and scavenging oxygen free radicals.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 922-922
Author(s):  
Janelle A. Olson ◽  
Robert Zeiser ◽  
Andreas Beilhack ◽  
Robert S. Negrin

Abstract Cell trafficking to distinct anatomical sites is critical for in vivo function. Natural Killer (NK) cells have been demonstrated to suppress graft-versus-host disease (GVHD) while inducing a graft-versus-tumor response (GVT). However, little is known about the homing of NK cells following bone marrow transplantation (BMT), their proliferative capacity and how long they persist in vivo. To investigate this, we transplanted highly purified DX5+ CD3− NK cells from FVB L2G85 luciferase+ mice into lethally irradiated syngeneic and BALB/c allogeneic recipients. Bioluminescence imaging (BLI) of transplant recipients revealed distinct NK cell migration to and proliferation in secondary lymphoid organs, which was confirmed by CFSE proliferation analysis. The allogeneic NK cells persisted for 20–30 days after which the signal gradually declined. Proliferation in lymphoid organs was undetectable in syngeneic recipients, but was enhanced by daily intraperitoneal injection of IL-2. Moderate proliferation in lymphoid organs and dramatic expansion in the thymus and peritoneal cavity were observed, which persisted for the duration of IL-2 administration. Exogenous IL-2 also increased NK cell proliferation in the allogeneic recipient thymus and peritoneal cavity, and even more robustly enhanced proliferation in the secondary lymphoid organs. Corresponding to this observed thymic homing, splenic NK cells reisolated from allogeneic recipients 5 days after transplant upregulated CCR9, a receptor important in thymocyte migration and homing of T cells to the gut. In this allogeneic setting, ex vivo imaging of the spleen and gut region 3 and 5 days after transplant confirmed localization of NK cells to the mesenteric lymph nodes, and also revealed NK cell infiltration of the small intestine, a major site of GVHD pathology in addition to the skin and liver. Additionally, donor NK cells were visible in the skin of transplanted animals by immunohistochemistry staining. Similar to T cells, a subset of freshly isolated NK cells express α4β7 and P-selectin ligand, expression of which are required for homing to the gut and skin, respectively. FACS analysis revealed that both these markers were upregulated on splenic NK cells reisolated from allogeneic recipients 5 days post-transplant. However, in contrast to T cells, CD62L was not downregulated on these NK cells. These results raised the question of whether the NK cell homing pattern observed in vivo and reflected in the upregulation of tissue-specific homing receptors is a consequence of the conditioning and transplant regime and associated inflammatory conditions, or whether NK cell alloreactivity can induce a specific trafficking pattern. To address this question, purified FVB luc+ NK cells were transplanted into unirradiated allogeneic BALB/c RAG2−/− γc −/− recipients, which lack T, B and NK cells. Moderate proliferation was seen in the spleen and lymph nodes, and infiltration of the gut tissue was observed. This implies that the inflammatory environment caused by tissue damage due to irradiation of recipients is not required for NK cell infiltration into GVHD target organs such as the gut. These studies indicate that NK cells are capable of proliferation in vivo either due to alloresponses or cytokine stimulation. Further, NK cells infiltrate GVHD target organs yet do not cause significant GVHD pathology possibly due to reduced tissue damage. NK cells may further reduce T cell proliferation in GVHD target sites through production of anti-inflammatory cytokines or by modulating antigen presentation.


Sign in / Sign up

Export Citation Format

Share Document